Lindsay Hracs

Lindsay Hracs

Auto-generated profile, based on publicly available information

Lindsay Hracs

Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2025 in Nature
Verified
Journal Article
Open access
PDF file
LHLindsay Hracs
Lindsay Hracs
JWJoseph W. Windsor
Joseph W. Windsor
JGJulia Gorospe
Julia Gorospe
MCMichael Cummings
Michael Cummings
SCStephanie Coward
Stephanie Coward
GKGilaad Kaplan
Gilaad Kaplan
During the twentieth century, inflammatory bowel disease (IBD) was considered a disease of early industrialized regions in North America, Europe and Oceania1. At the turn of the twenty-first century, IBD incidence increased in newly industrialized and emerging regions in Africa, Asia and Latin America, while the prevalence in early industrialized regions continued to grow steadily2,3,4. Changes in the incidence and prevalence denote the evolution of IBD across four epidemiologic stages: stage 1 (emergence), characterized by low incidence and prevalence; stage 2 (acceleration in incidence), marked by rapidly rising incidence and low prevalence; and stage 3 (compounding prevalence), where the incidence decelerates, plateaus or declines while the prevalence steadily increases. A fourth stage (prevalence equilibrium) has been proposed in which the prevalence slope plateaus due to demographic shifts in an ageing IBD population, but it has not yet been evidenced. To date, these stages have remained theoretical, lacking specific numerical indicators to define transition points. Here, using real-world data from 522 population-based studies encompassing 82 global regions and spanning more than a century (1920–2024), we show spatiotemporal transitions across stages 1–3 and model stage 4 progression. Understanding the evolution of IBD across epidemiologic stages enables healthcare systems to better anticipate the future worldwide burden of IBD.

1 February 2024 in American Journal of Gastroenterology
Verified
Journal Article
Open access
SCStephanie Coward
Stephanie Coward
EBEric I. Benchimol
Eric I. Benchimol
CBCharles N. Bernstein
Charles N. Bernstein
AAAntonio Avina-Zubieta
Antonio Avina-Zubieta
ABAlain Bitton
Alain Bitton
O(on behalf of the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC)
on behalf of the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC)
INTRODUCTION: Canada has a high burden of inflammatory bowel disease (IBD). Historical trends of IBD incidence and prevalence were analyzed to forecast the Canadian burden over the next decade. METHODS: Population-based surveillance cohorts in 8 provinces derived from health administrative data assessed the national incidence (2007–2014) and prevalence (2002–2014) of IBD. Autoregressive integrated moving average models were used to forecast incidence and prevalence, stratified by age, with 95% prediction intervals (PI), to 2035. The average annual percentage change (AAPC) with 95% confidence interval (CI) was calculated for the forecasted incidence and prevalence. RESULTS: The national incidence of IBD is estimated to be 29.9 per 100,000 (95% PI 28.3–31.5) in 2023. With a stable AAPC of 0.36% (95% CI −0.05 to 0.72), the incidence of IBD is forecasted to be 31.2 per 100,000 (95% PI 28.1–34.3) in 2035. The incidence in pediatric patients (younger than 18 years) is increasing (AAPC 1.27%; 95% CI 0.82–1.67), but it is stable in adults (AAPC 0.26%; 95% CI −0.42 to 0.82). The prevalence of IBD in Canada was 843 per 100,000 (95% PI 716–735) in 2023 and is expected to steadily climb (AAPC 2.43%; 95% CI 2.32–2.54) to 1,098 per 100,000 (95% PI 1,068–1,127) by 2035. The highest prevalence is in seniors with IBD (1,174 per 100,000 in 2023; AAPC 2.78%; 95% CI 2.75–2.81). DISCUSSION: Over the next decade, the Canadian health care systems will contend with the juxtaposition of rising incidence of pediatric IBD and a rising prevalence of overall IBD driven by the aging population.

24 November 2025 in American Journal of Gastroenterology
Verified
Journal Article
Open access
JWJoseph W. Windsor
Joseph W. Windsor
SCStephanie Coward
Stephanie Coward
LHLindsay Hracs
Lindsay Hracs
JMJoyce W. Y. Mak
Joyce W. Y. Mak
RBRupa Banerjee
Rupa Banerjee
GKGilaad Kaplan
Gilaad Kaplan
INTRODUCTION: The ulcerative colitis (UC) to Crohn's disease (CD) incidence ratio varies across geography and time. METHODS: We analyzed UC:CD incidence ratios across 3 epidemiologic stages using generalized additive models for location, shape, and scale and pooled average annual percent changes by meta-analysis. RESULTS: Ratios significantly decreased: median 3.62 in stage 1, 1.82 in stage 2, 1.55 in stage 3; the incidence ratio stabilized in stage 3 (average annual percent change: −0.12; 95%CI: −0.66, 0.42). DISCUSSION: Decreasing UC:CD incidence ratios signal a rising burden of CD, underscoring the need to anticipate greater health care demand, including higher treatment costs and higher prevalence of complications.

22 June 2023 in American Journal of Gastroenterology
Verified
Journal Article
Open access
AMAnte Markovinović
Ante Markovinović
JQJoshua Quan
Joshua Quan
MHMichelle Herauf
Michelle Herauf
LHLindsay Hracs
Lindsay Hracs
JWJoseph W. Windsor
Joseph W. Windsor
GKGilaad Kaplan
Gilaad Kaplan
INTRODUCTION: We determined adverse events after 4 doses of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine in those with inflammatory bowel disease (IBD), associations between antibodies and injection site reactions (ISR), and risk of IBD flare. METHODS: Individuals with IBD were interviewed for adverse events to SARS-CoV-2 vaccine. Multivariable linear regression assessed the association between antibody titers and ISR. RESULTS: Severe adverse events occurred in 0.03%. ISR were significantly associated with antibody levels after the fourth dose (geometric mean ratio = 2.56; 95% confidence interval 1.18–5.57). No cases of IBD flare occurred. DISCUSSION: SARS-CoV-2 vaccines are safe for those with IBD. ISR after the fourth dose may indicate increased antibodies.

23 January 2024 in Research Square
Verified
Preprint
Open access
PDF file
GKGilaad Kaplan
Gilaad Kaplan
LHLindsay Hracs
Lindsay Hracs
JWJoseph Windsor
Joseph Windsor
JGJulia Gorospe
Julia Gorospe
MCMichael Cummings
Michael Cummings
SNSiew C Ng
Siew C Ng
During the 20th century, inflammatory bowel disease (IBD) was considered a disease of early-industrialized regions in North America, Europe, and Oceania. At the turn of the 21st century, incidence of IBD increased in newly-industrialized and emerging regions in Africa, Asia, and Latin America, while prevalence in early-industrialized regions started to grow steadily. Changes in incidence and prevalence denote evolution of IBD across four epidemiologic stages: Stage 1 (Emergence), characterized by low incidence and prevalence; stage 2 (Acceleration in Incidence), characterized by rapidly rising incidence and low prevalence; and stage 3 (Compounding Prevalence), characterized by decelerating, plateauing, or declining incidence and steadily rising prevalence. A fourth stage (Prevalence Equilibrium) has been proposed where the slope of prevalence plateaus due to shifting demographics of an aging IBD population, but it has not yet been evidenced. To date, these stages have been theoretical without specific incidence/prevalence indicators defining transition points. Using real-world data from 490 population-based studies comprising 80 global regions and spanning over a century (1920–2023), we show spatiotemporal transitions across stages 1–3 and model transition towards stage 4. Understanding the evolution of IBD across epidemiologic stages allows healthcare systems to better prepare for the future worldwide burden of IBD.

13 August 2024
Verified
Book Chapter
Closed access
LHLindsay Hracs
Lindsay Hracs